MiR-92a-1-5p contributes to cellular proliferation and survival in chronic myeloid leukemia and its inhibition enhances imatinib efficacy
Authors:
- Joanne PetersJPJoanne Peters
- Emeline BollaertEBEmeline Bollaert
- Anne-Sophie CloosACAnne-Sophie Cloos
- Melissa ClausMCMelissa Claus
- Ahmed EssaghirAEAhmed Essaghir
- Sandrine LenglezSLSandrine Lenglez
- Pascale SaussoyPSPascale Saussoy
- Guillaume DachyGDGuillaume Dachy
- Pierre AutinPAPierre Autin
- Jean-Baptiste DemoulinJDJean-Baptiste Demoulin
- Violaine HavelangeVHViolaine Havelange
Open Access
- 1 October 2025
- journal article
- Published by KEAI Publishing in Non-coding RNA Research
- Vol. 14, 14-24
Abstract
Tyrosine kinase inhibitors (TKI), such as imatinib, have revolutionized chronic myeloid leukemia (CML) treatment. Despite this success, TKI intolerance and resistance remain significant clinical challenges. A promising therapeutic approach is to simultaneously target the BCR::ABL1 oncogene and other oncogenic drivers. The polycistronic miR-17-92 cluster is known to contribute to CML development and progression, but the specific roles of miR-92a-1-5p within this cluster remain unclear. In this study, we assess the roles of this microRNA and evaluate the therapeutic potential of combining microRNA inhibition with imatinib to improve treatment outcome. Our results show that miR-92a-1-5p is downregulated by imatinib in myeloid cell lines harboring BCR::ABL1 and in CML patient samples. Inhibition of miR-92a-1-5p reduces proliferation and enhances imatinib-induced cell death, while its overexpression increases proliferation and counteracts the effects of imatinib on cell death. This decrease in proliferation caused by miR-92a-1-5p inhibition is rescued after simultaneous inhibition of two newly identified target genes: BNIP3L (NIX) and TP53INP1. We confirm that miR-92a-1-5p regulates proliferation and cell cycle by targeting TP53INP1 and decreases autophagy by targeting BNIP3L. Our data suggest that miR-92a-1-5p plays a role in CML progression, and its inhibition enhances imatinib anti-leukemic efficacy, making it a potential therapeutic target.Keywords
This publication has 35 references indexed in Scilit:
- Expression patterns of microRNAs associated with CML phases and their disease related targetsMolecular Cancer, 2011
- The miR-17-92 Cluster of MicroRNAs Confers Tumorigenicity by Inhibiting Oncogene-Induced SenescenceCancer Research, 2010
- BNIP3 subfamily BH3-only proteins: mitochondrial stress sensors in normal and pathological functionsOncogene, 2008
- Targeting erythroblast-specific apoptosis in experimental anemiaApoptosis, 2008
- miRiad Roles for the miR-17-92 Cluster in Development and DiseaseCell, 2008
- Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cellsBlood, 2007
- TP53INP1 is a novel p73 target gene that induces cell cycle arrest and cell death by modulating p73 transcriptional activityOncogene, 2005
- TP53INP1s and Homeodomain-interacting Protein Kinase-2 (HIPK2) Are Partners in Regulating p53 ActivityJournal of Biological Chemistry, 2003
- Chronic myelogenous leukemia: mechanisms underlying disease progressionLeukemia, 2002
- Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid LeukemiaNew England Journal of Medicine, 2001